This conclusion partly aligns with recent reports [27–30], whereby prognosis of cancer patients is negatively correlated with elevated serum IL-8 expression levels, diminishes the clinical efficacy of immune checkpoint inhibitors, and can serve as an independent biomarker for patients receiving immune checkpoint inhibitors [31]. Here, CXCL8 is linked to cancer.